SAINT LAURENT, Quebec, May 12, 2021 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX-V: IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it has entered into a second feasibility agreement (the “SFA”) with ATAI Life Sciences AG (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications…
